Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital upgrades Crest Nicholson to 'outperform', lifts price target

(Sharecast News) - RBC Capital Markets upgraded Crest Nicholson on Friday to 'outperform' from 'sector perform' and hiked the price target to 230p from 180p after the housebuilder's capital markets day on Thursday. "Crest Nicholson's new chief executive has a plan," the bank said.

"He has cast his eye over the group and, perhaps in homage to the late great Eric Morecambe, has concluded that Crest has all the pieces it needs for success, but has been playing them in the wrong order.

"The group now has a chance to return to growth in volumes, margins and returns. With its operational issues now largely behind it, the future has got brighter."

RBC said that by FY2029, it believes Crest could look like "the Redrow of the South".

It noted that Crest's new strategy is to focus on the mid-premium sector. Rather than try to build all homes for all people it is focused on those with more money who are able to afford some of the finer things in life, RBC said.

It said that typically these are households with more equity than typical first time buyers and those willing to pay more for bigger rooms, higher ceilings and higher specifications, "because, as some might say, they are worth it".

RBC said that while it does not believe that Crest needs rocket fuel to reach its targets, the capital markets day "did not allow us to kick the tires as much as we'd like".

"We felt the detail around landbank margins and strategic land was somewhat vague, leading us to believe that either the margin and return guidance is too low or the embedded margins are not as high as they seem," RBC said.

As a result, the bank's new price target is based on a P/B multiple of 0.75x "to reflect the known unknowns".

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.